Respiratory virus infections after allogeneic stem cell transplantation: Current understanding, knowledge gaps, and recent advances.
José Luis PiñanaAriadna PérezPedro ChorãoManuel GuerreiroIrene García-CadenasCarlos SolanoRodrigo MartinoDavide Navarronull nullPublished in: Transplant infectious disease : an official journal of the Transplantation Society (2023)
Before the COVID-19 pandemic, common community-acquired seasonal respiratory viruses (CARVs) were a significant threat to the health and well-being of allogeneic hematopoietic cell transplant (allo-HCT) recipients, often resulting in severe illness and even death. The pandemic has further highlighted the significant risk that immunosuppressed patients, including allo-HCT recipients, face when infected with SARS-CoV-2. As preventive transmission measures are relaxed and CARVs circulate again among the community, including in allo-HSCT recipients, it is crucial to understand the current state of knowledge, gaps, and recent advances regarding CARV infection in allo-HCT recipients. Urgent research is needed to identify seasonal respiratory viruses as potential drivers for future pandemics.
Keyphrases
- stem cell transplantation
- healthcare
- sars cov
- high dose
- kidney transplantation
- mental health
- end stage renal disease
- bone marrow
- newly diagnosed
- public health
- chronic kidney disease
- coronavirus disease
- hematopoietic stem cell
- respiratory tract
- prognostic factors
- respiratory syndrome coronavirus
- cell therapy
- low dose
- cell death
- patient reported outcomes
- human health
- stem cells
- climate change
- health information
- signaling pathway
- risk assessment